|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome显示文摘 | Yost C C Soll R F | | 0，，02： | 1 |
| 2 | Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants显示文摘 | Soll R F | | 0，，02： | 1 |
| 3 | Exogenous surfactant therapy in newborn infants显示文摘 | Suresh G K Soll R F | 2003 | Ann Acad Med Singapore2003，32，： | 1 |
| 4 | Current Trials in the Treatment of Respiratory Failure in Preterm Infants显示文摘 | Soll R F | | 0，，21： | 1 |
| 5 | Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas显示文摘 | Riener M O Fritzsche F R Soll C Pestalozzi B C Probst Hens-ch N Clavien P A | 2010 | Histopathology2010，56，： | 1 |
| 6 | 14-3-3 proteins and plant development显示文摘 | Fulgosi H Soll J Maraschin S de F Korthout H A A J Wang M Testerink C | | 0，，： | 1 |
| 7 | Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome显示文摘 | Soll RF Blanco F | 2001 | Cochrane Database Syst Rev2001，，00： | 1 |
| 8 | Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome 显示文摘 | Bahadue F L Soll R | 2012 | Cochrane Database Syst Rev2012，11，00： | 1 |
| 9 | A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome显示文摘 | Horbar J D Wright L L Soll R F | 1993 | J Pediatr1993，123，： | 1 |
| 10 | Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants显示文摘 | SOLL R F MORLEY C J | 2000 | Cochrane Database Syst Rev2000，，00： | 1 |
| 11 | Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits显示文摘 | Scheppke Lea Aguilar Edith Gariano Ray F Jacobson Ruth Hood John Doukas John Cao Jon Noronha Glenn Yee Shiyin Weis Sara Martin Michael B Soll Richard Cheresh David A Friedlander Martin | 2008 | Journal of Clinical Investigation2008，，6： | 1 |
| 12 | Systematic analysis of oxidative degradation of polysaccharides using PAGE and HPLC-MS 显示文摘 | Ovalle R Soll CE Lim F | 2001 | (2arbohyd Res2001，330，1： | 1 |
| 13 | Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants显示文摘 | SOLL R F MORLEY C J | 2001 | Cochrane Database Syst Rev2001，，00： | 1 |
| 14 | Combined evaluation of biomarkers as predictor of maintained remission in Crohn's disease显示文摘BACKGROUND The individual performances and the complementarity of Crohn's disease(CD)activity index(CDAI), C-reactive protein(CRP) and faecal calprotectin(Fcal) to monitor patients with CD remain poorly inves-tigated in the era of 'tight control'and 'treat to target' strategies.AIM To assess CDAI, CRP and Fcal variation, alone or combined, after 12 wk(W12) of anti-tumor necrosis factor(TNF) therapy to predict corticosteroids-free remission(CFREM = CDAI < 150, CRP < 2.9 mg/L and Fcal < 250 μg/g with no therapeutic intensification and no surgery) at W52.METHODS CD adult patients needing anti-TNF therapy with CDAI > 150 and either CRP >2.9 mg/L or Fcal > 250 μg/g were prospectively enrolled.RESULTS Among the 40 included patients, 13 patients(32.5%) achieved CFREM at W52. In univariable analysis, CDAI < 150 at W12(P = 0.012), CRP level < 2.9 mg/L at W12(P = 0.001) and Fcal improvement at W12(Fcal < 300 μg/g; or, for patients with initial Fcal < 300 μg/g, at least 50% decrease of Fcal or normalization of Fcal(< 100 μg/g)(P = 0.001) were predictive of CFREM at W52. Combined endpoint(CDAI < 150 and CRP ≤ 2.9 mg/L and FCal improvement) at W12 was the best predictor of CFREM at W52 with positive predictive value = 100.0%(100.0-100.0)and negative predictive value = 87.1%(75.3-98.9). In multivariable analysis, Fcal improvement at W12 [odd ratio(OR) = 45.1(2.96-687.9); P = 0.03] was a better predictor of CFREM at W52 than CDAI < 150 [OR = 9.3(0.36-237.1); P = 0.145]and CRP < 2.9 mg/L(0.77-278.0; P = 0.073).CONCLUSION The combined monitoring of CDAI, CRP and Fcal after anti-TNF induction therapy is able to predict favorable outcome within one year in patients with CD. | Elisa Sollelis Régine Minet Quinard Guillaume Bouguen Marion Goutte Félix Goutorbe Damien Bouvier Bruno Pereira Gilles Bommelaer Anthony Buisson | 2019 | World Journal of Gastroenterology2019，25，19： | 1 |
| 15 | Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome显示文摘 | Soll RF Blanco F | 2001 | Cochrane Database Syst Rev2001，，： | 1 |
| 16 | Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome 显示文摘 | Soll RF Blanco F | 2001 | Gochrane Database Syst Rev2001，，00： | 1 |
| 17 | Clinical trials of natural suffaetant extract in re- spiratory distress syndrome显示文摘 | Mercier C E Soll R F | 1993 | Clin Perinatol1993，20，4： | 1 |
| 18 | Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome显示文摘 | Soll RF Blanco F | 2001 | Cochrane Database Syst Rev2001，，： | 1 |
| 19 | Systematic analysis of oxidative degradation of polysaccharides using PAGE and HPLC-MS 显示文摘 | Ovalle R Soll C E Lim F L | 2001 | Carbohydrate Research2001，330，1： | 1 |
| 20 | Intermediate Gas Phase Precursors During Plasma CVD of HMDSO显示文摘 | THEIRICH D SOLL Ch LEU F | 2003 | D Theirich et al2003，，71： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员